Genscript Biotech's (HKG:1548) associate Legend Biotech will present preliminary clinical data for LB2501 at a late-breaking session at the European Hematology Association 2026 Congress, according to a Tuesday Hong Kong bourse filing.
Shares of the cancer drug company were up nearly 11% in Wednesday afternoon trading.
The data is for the drug being tested in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
The conference will take place from June 11 to 14 in Stockholm, Sweden.
Jointown Pharmaceutical's (SHA:600998) subsidiary, Beijing Jingfeng Pharmaceutical (Shandong), received approval from China's National Medical Products Administration for the marketing of its active pharmaceutical ingredient, azelastine hydrochloride, according to a Shanghai bourse filing on Wednesday.The drug is a selective histamine H1 receptor antagonist with antihistamine and anti-allergic properties.
China South Publishing & Media (SHA:601098) agreed to supply education resources to the local government of China's Hunan Province for 966.9 million yuan, according to a Shanghai bourse filing on Wednesday.The publishing company will provide textbooks, thematic education readers and other learning resources to up to 8 million students for the year.
Shanghai Zhonggu Logistics (SHA:603565) plans to raise up to 3 billion yuan through the issuance of a convertible bond, according to a Shanghai bourse filing on Tuesday.Proceeds from the issuance will be used to fund a container vessel acquisition project.The convertible bond will have a term of six years.The logistics services provider's shares slumped 6% at the close.